Persistent Respiratory Failure and Re-Admission in Patients with Chronic Obstructive Pulmonary Disease Following Hospitalization for COVID-19.

Autor:	Figueira-Gonçalves JM; Pneumology and Thoracic Surgery Service, Unit for Patients with Highly Complex COPD, University Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.; University Institute of Tropical Disease and Public Health of the Canary Islands, University of La Laguna, Santa Cruz de Tenerife, Spain., García-Bello MÁ; Evaluation Unit (SESCS), Canary Islands Health Research Institute Foundation (FIISC), Tenerife, Spain.; Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), Tenerife, Spain., Ramallo-Fariña Y; Evaluation Unit (SESCS), Canary Islands Health Research Institute Foundation (FIISC), Tenerife, Spain.; Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), Tenerife, Spain.; Health Services Research on Chronic Patients Network (REDISSEC), Madrid, Spain., Méndez R; Pneumology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.; Respiratory InFections, Instituto de Investigación Sanitaria La Fe (IISLAFE), Valencia, Spain.; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.; Medicine Department, University of Valencia, Valencia, Spain., Latorre Campos A; Pneumology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.; Respiratory InFections, Instituto de Investigación Sanitaria La Fe (IISLAFE), Valencia, Spain., González-Jiménez P; Pneumology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.; Respiratory InFections, Instituto de Investigación Sanitaria La Fe (IISLAFE), Valencia, Spain.; Medicine Department, University of Valencia, Valencia, Spain., Peces-Barba G; Pulmonology Department, Hospital Fundación Jiménez Díaz, Madrid, Spain., Molina-Molina M; ILD Unit, Respiratory Department, Hospital de Bellvitge, Hospitalet de Llobregat, Spain., España PP; Respiratory Service, Hospital de Galdakao-Usansolo, Galdakao, Spain., García E; Respiratory Service, Hospital de Cabueñes, Gijón, Spain., Domínguez-Pazos SJ; Respiratory Service, Hospital Universitario de A Coruña, A Coruña, Spain., García Clemente M; Respiratory Service, Hospital Universitario Central de Asturias, Oviedo, Spain., Panadero C; Respiratory Service, Hospital de Getafe, Getafe, Spain., de la Rosa-Carrillo D; Respiratory Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Sibila O; Respiratory Service, Hospital Clínic, Barcelona, Spain., Martínez-Pitarch MD; Respiratory Service, Hospital Lluís Alcanyís, Játiva, Spain., Toledo-Pons N; Respiratory Service, Hospital Son Espases, Palma, Spain., López-Ramirez C; Medical Surgical Unit of Respiratory Diseases, Hospital Virgen del Rocío, Sevilla, Spain., Almonte-Batista W; Respiratory Service, Hospital de Albacete, Albacete, Spain., Macías-Paredes A; Respiratory Service, Hospital de Sant Jaume, Calella, Spain., Badenes-Bonet D; Respiratory Service, Hospital del Mar, Barcelona, Spain., Pérez-Rodas EN; Respiratory Service, Hospital Municipal de Badalona, Badalona, Spain., Lázaro J; Respiratory Service, Hospital Royo Villanova, Zaragoza, Spain., Quirós Fernández S; Respiratory Service, Hospital Basurto, Bilbao, Spain., Cordovilla R; Respiratory Service, Hospital de Salamanca, Salamanca, Spain., Cano-Pumarega I; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.; Respiratory Service, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain., Torres A; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.; Respiratory Service, Hospital Clínic, Barcelona, Spain., Menendez R; Pneumology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.; Respiratory InFections, Instituto de Investigación Sanitaria La Fe (IISLAFE), Valencia, Spain.; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.; Medicine Department, University of Valencia, Valencia, Spain.
Jazyk:	angličtina
Zdroj:	International journal of chronic obstructive pulmonary disease [Int J Chron Obstruct Pulmon Dis] 2023 Nov 07; Vol. 18, pp. 2473-2481. Date of Electronic Publication: 2023 Nov 07 (Print Publication: 2023).
DOI:	10.2147/COPD.S428316
Abstrakt:	Background: Chronic obstructive pulmonary disease (COPD) has been associated with worse clinical evolution/survival during a hospitalization for SARS-CoV2 (COVID-19). The objective of this study was to learn the situation of these patients at discharge as well as the risk of re-admission/mortality in the following 12 months. Methods: We carried out a subanalysis of the RECOVID registry. A multicenter, observational study that retrospectively collected data on severe acute COVID-19 episodes and follow-up visits for up to a year in survivors. The data collection protocol includes general demographic data, smoking, comorbidities, pharmacological treatment, infection severity, complications during hospitalization and required treatment. At discharge, resting oxygen saturation (SpO2), dyspnea according to the mMRC (modified Medical Research Council) scale and long-term oxygen therapy prescription were recorded. The follow-up database included the clinical management visits at 6 and 12 months, where re-admission and mortality were recorded. Results: A total of 2047 patients were included (5.6% had a COPD diagnosis). At discharge, patients with COPD had greater dyspnea and a greater need for prescription home oxygen. After adjusting for age, sex and Charlson comorbidity index, patients with COPD had a greater risk of hospital re-admission due to respiratory causes (HR 2.57 [1.35-4.89], p = 0.004), with no significant differences in survival. Conclusion: Patients with COPD who overcome a serious SARS-CoV2 infection show a worse clinical situation at discharge and a greater risk of re-admission for respiratory causes. Competing Interests: Dr Pedro Pablo España reports personal fees from Glaxo, grants from Pfizer, outside the submitted work. Drs Nuria Toledo-Pons reports personal fees from GSK, Chiesi; non-financial support from FAES and Sanofi, outside the submitted work. The authors report no other conflicts of interest in this work. (© 2023 Figueira‐Gonçalves et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu